1. Introduction {#s0005}
===============

Breast cancer, that represents nearly 1/4th of total cancers diagnosed in female ([@b0045]), results from the interaction between multiple genes and environmental factors ([@b0090]) ([@b0285]).

CTCF (CCCTC-binding factor) regulates gene expression through activation/repression of the promoter, chromatin lining and imprinting of genomes ([@b0185]), along with involvement in the establishment of the 3D structure of the genome and genomic segments ([@b0080]). It also has a tumor suppressor function and is commonly deleted or mutated in breast cancer cell lines and breast tumors ([@b0085], [@b0095], [@b0220], [@b0265]).

11-zinc fingers enable the protein to bind diverse gene sequences making it a universal transcription factor ([@b0110], [@b0170]). CTCF is a tumor suppressor suspects linked with familial breast cancer ([@b0180]). Genomic platforms and integration of sequence data suggest that *CTCF* may harbor driver mutation in breast cancer ([@b0025], [@b0175]). CTCF protein levels are elevated in many breast tumors as well as cancer cell lines ([@b0035]). The epigenetic control of the *BAX* gene by CTCF helps the cancer cells to evade apoptosis in addition to influencing genome imprinting, intronic transcription, inactivation of X-chromosome, and post-transcription processing ([@b0035], [@b0160]). It further downregulates the transcription of the *c-Myc* oncogene and impacts the expression of maternal H19 allele ([@b0075]), as well as establishes chromatin boundaries and mediating long-range chromatin interactions ([@b0195]).

16q22-24 region, the location of *CTCF*, commonly exhibits loss of heterozygosity (LOH) in breast cancer ([@b0125], [@b0030]). Interestingly, this phenomenon is associated with longer survival and delayed metastasis ([@b0125], [@b0065]).

*CTCF* can be deregulated in multiple ways, including germline and somatic (missense and nonsense) mutations resulting in the onset and progression of genetic disorders like human cancers ([@b0140], [@b0050], [@b0215]). The *CTCF* gene mutation(s) leading to many human cancers strongly suggest the critical loss of function as important as tumor suppression ([@b0155], [@b0180], [@b0050]).

An early *in vitro* report indicated the anti-proliferative activity of CTCF by showing that it repressed the cell proliferation ([@b0145]). However, the precise role of CTCF in the onset or progression of cancer remains to be elucidated. The efforts have been made in many human tumors, but breast cancer is scarcely studied ([@b0245], [@b0055], [@b0290], [@b0005], [@b0260]).

The current study aimed to find mutations in various hot spot exons of *CTCF* by polymerase chain reaction-single stranded conformation polymorphism (PCR-SSCP) followed by sequencing of DNA isolated from cancerous and adjacent normal breast tissues to identify mutational hot spots of *CTCF* contributing to carcinogenesis. Additionally, the expression of CTCF protein was also analyzed to show the relationship between *CTCF* mutation and its expression with various clinico-pathological parameters.

2. Materials and Methods {#s0010}
========================

2.1. Biological samples {#s0015}
-----------------------

The subjects were informed, and consent forms were collected from all the participants after the ethical clearance from the institutional ethics committee of All India Institute of Medical Sciences (AIIMS), New Delhi, India. 155 female breast cancer tissue samples and an equal number of adjacent normal tissues (measuring 5--10 mm), were obtained and stored in PBS and formalin between 2010 and 2014 from the Department of Surgical Oncology, AIIMS, New Delhi India. Breast cancer stages were determined using the TNM staging system or American Joint Committee on Cancer (AJCC). The clinicopathological variables are age, histological type, tumor size, histological grade, menopausal status, tumor stage*,* nodal status, ER expression, PR expression and Her2/Neu.

2.2. DNA isolation {#s0020}
------------------

DNA was isolated from the cases and healthy control tissue by using the standard phenol/chloroform method as described previously ([@b0225]). DNA concentration and purity were determined using electrophoresis and UV spectrophotometry before storing it in TE buffer.

2.3. PCR-SSCP analysis {#s0025}
----------------------

Hot spot exon 1 and 4 of *CTCF* gene were probed for the presence of mutation using the tumor and normal control DNA with the primers ([table 1](#t0005){ref-type="table"}). PCR product showed the presence of 206 bp and 246 bp amplicons ([Fig. 1](#f0005){ref-type="fig"}) as identifed by using Quantity One Software **(**Bio-Rad Laboratories**,** CA, USA). The purified product was assayed for any alteration in the electrophoretic mobility as described previously ([@b0190]). Comparison of single-stranded DNA bands of the tumor and normal control to the identification of SSCP positive samples ([Fig. 2](#f0010){ref-type="fig"}).Table 1Oligonucleotide primer sequences used for amplification of different exons.**GeneConsensus sequenceAnnealing temperature (^o^c)Amplicon size (bp)***CTCF* Exon 1 FP5′- GGTGATGATGGAACAGCTGG -3′60206*CTCF* Exon 1 RP5′- TGGTAGCAACAGGTACAGTC -3′*CTCF* Exon 4 FP5′-TCACATTCGCTCTCATACTGG-3′58246*CTCF* Exon 4 FP5′-CGGAGAAGCATTATCAATTC-3′Fig. 1Amplified exon products (206 and 246 bp) of CTCF gene. Lane L: Molecular marker of 100 bp, Lanes 1--7: Amplicons from the Breast cancer tissues samples.Fig. 2SSCP (non-radio active) analysis of CTCF gene shows a variation/ shift in band pattern lane 2, 3, 5, 6, 7 and 8 of the breast tumor samples when compared with normal sample in lane 1.

2.4. DNA sequencing {#s0030}
-------------------

The SSCP positive samples were re-amplified and purified before sequencing twice to prevent the formation of any artifacts (ABI PRISM310 dye Terminator Cycle Sequencing Ready reaction Kit) and analyzed using Sequencing Analysis Software 3.4.1 ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Representative partial electropherograms of Mutant (B) (shown by arrow) with Normal (A) adjacent forms of CTCF gene showing substitutin G\>T.

2.5. IHC analysis {#s0035}
-----------------

Immunohistochemical staining was done to assess CTCF protein expression using the anti-human CTCF antibody (GeneScript, USA, Catalog \# A01529) ([@b0010]). Briefly, breast cancer tissue samples cut into 2 to 4 μm section embedded in poly-L- lysine coated slides were treated with xylene, alcohol, and heat to retrieve the antigen. The slides were finally incubated with anti-CTCF antibody and developed using straptavidin Horse-reddish peroxidase detection kit (GeneScript USA). Slides scoring as Low or no expression (+), Moderate (++) and High expression (+++) representation of number and distribution of cells among cases and controls was done using Olympus BX 50, Tokyo.

2.6. Statistical analysis {#s0040}
-------------------------

Chi-square test (χ2) was used to assess the association of *CTCF* mutation and its expression with various clinicopathological parameters using GraphPad Prism 6.0. The *P*-value ≤ 0.05 was considered significant.

3. Results {#s0045}
==========

3.1. Mutation(s) in *CTCF* and clinicopathological parameters {#s0050}
-------------------------------------------------------------

A total of 25 (16.12%) breast cancer cases showed mutations in the exon 1 and exon 4 including a missense mutation (Gln \> His, G \> T) in seventeen cases and silent mutation (Ser \> Ser, C \> T) in eight cases ([Table 2](#t0010){ref-type="table"}) ([Fig. 6](#f0030){ref-type="fig"}).Table 2Details of CTCF gene Mutation(s) in Female Breast Cancer Cases from India.**Affected CodonBase PositionBase ChangeAmino Acid ChangeMutation EffectNo. of Patients**72216CA**G** \> CA**T (G \> T)**Glutamine \> Histidine (Gln \> His)Missense173881455TC**C** \> TC**T (C \> T)**Serine \> Serine (Ser \> Ser)Silent08

No mutation was observed in normal control samples. The relationship between *CTCF* mutations and clinicopathological parameters showed a significant correlation with patients menopausal status *(p = 0.02)*, tumor stage *(p = 0.03),* nodal status *(p = 0.03)* and estrogen receptor (*ER*) expression (*p = 0.04* ([Table 3](#t0015){ref-type="table"}). However, the association with age, histological type, tumor size, histological grade, progesterone receptor (*PR*) expression, and *Her2/Neu* failed to reach statistical significance.Table 3Correlation between mutations of human *CTCF* gene with clinicopathological parameters.**Number of patients155ParametersNo. of cases (n = 155)MutationsMutation rate (%)χ2 valueP valueAge**\>50801620.001.8310.176≤50750912.00**Menopausal status**Pre70068.575.390**0.020**\*\*Post851922.35**Histological Type**Invasive ductal Carcinoma1502516.670.9930.318(IDC)Invasive lobular carcinoma000.0005(ILC)**Tumor Size**≤2cm650710.772.3770.123˃2cm901820.00**Histological Grade**Poorly differentiated (PD)400512.501.5960.450Moderately differentiated (MD)691420.29Well differentiated (WD)460613.04**Tumor Stage**Stage II (a+b)730709.594.363**0.036**\*\*Stage III (a+b) + IV821821.95**Nodal Status**Positive811822.224.656**0.030**\*\*Negative740709.46**Estrogen Receptor (ER) Expression**Positive720709.724.080**0.043**\*\*Negative831821.68**Progesterone Receptor (PR) Status**Positive660812.121.3650.242Negative891719.10**Her2/Neu**Positive690710.143.2920.069Negative861820.93[^1]

3.2. *CTCF* expression and clinicopathological features {#s0055}
-------------------------------------------------------

Of all 155 cases, 66 (42.59%) showed low/ no expression (+), 59 cases (38.06%) with moderate (++) expression and 30 cases (19.35%) had high (+++) expression for CTCF nuclear staining ([Table 4](#t0020){ref-type="table"}, [Fig. 5](#f0025){ref-type="fig"}). A significant correlation was detected between CTCF protein expression and histological grade (*p* = 0.04), nodal status (*p* = 0.03), tumor stage (*p* = 0.04), and *ER* status (*p* = 0.04) ([Table 5](#t0025){ref-type="table"}). However, the association with age (*p* = 0.29), menopausal status (*p* = 0.84), histological type (*p* = 0.56), tumor size (*p* = 0.464), *PR* status (*p* = 0.10) and *Her2/Neu* (*p* = 0.49) failed to reach significance ([Table 5](#t0025){ref-type="table"}).Table 4Profile of CTCF protein expression.**CTCF gene expression**Low66/15542. 59%Moderate59/15538. 06%High30/15519. 35%Fig. 4Impact of mutation on CTCF protein.Fig. 5Representative Immunohistochemical slides (seen at 10X) showing (a) Low expression (+), (b) Moderate expression (++), (c) High expression (+++) of CTCF protein in Indian female breast cancer cases and (d) CTCF protein expression in normal control.Fig. 6Graphical abstract.Table 5Correlation between the expression of *CTCF* protein and Clinico-pathological parameters of breast carcinoma.**Parametersn=155LowNormalHighχ2p valueAge**˃50803514312.4470.294≤5075292125**Menopausal status**Pre703214240.3280.848Post85351832**Histological Type**Invasive Ductal Carcinoma (IDC)1506039511.1580.560Invasive Lobular Carcinoma (ILC)05020201**Tumour Size**≤2cm652318241.5320.464˃2cm90402426**Histological Grade**First4020091109.791**0.044**\*\*Second69232521hird46121123**Tumor stage**Stage2 (a+b)732318326.079**0.047**\*\*Stage3 (a+b) +482382321**Nodal status**Positive813821226.824**0.033**\*\*Negative74241535**ER status**Positive722217336.008**0.049**\*\*Negative83401924**PR Status**Positive (+ve)663612184.4750.106Negative (−ve)89342629**Her2/Neu**Positive (+ve)692419261.4130.493Negative (−ve)86382028

3.3. Correlation between mutation(s) and expression of *CTCF* cases {#s0060}
-------------------------------------------------------------------

The mutation(s) found in the breast cancer patients was analyzed along with *CTCF* expression to elucidate the potential role of *CTCF* in breast cancer. The relationship of *CTCF* mutation with its expression was observed significantly in the case of low level (+) protein expression (*p* = 0.03). However, the link in cases of moderate (++) (*p* = 0.11) and high level (+++) (*p* = 0.43) protein expression was found not significant ([Table 6](#t0030){ref-type="table"}).Table 6Correlation between mutations and protein expression of CTCF gene in breast cancer patients**Level of expressionNo. of cases (n = 155)Mutations (25/155 = 16.12%)χ2p-value**Low69/155 (44.52%)16/155 (10.32%)4.581**0.032\*\***Moderate59/155 (38.06%)06/155 (3.87%)2.5010.113High27/155 (17.42%)03/155 (1.93%)0.6080.435

4. Discussion {#s0065}
=============

Aberrant *CTCF* is linked with several diseases/disorders, including cancer ([@b0005], [@b0200], [@b0070], [@b0060], [@b0015]). The tumor suppressor function of CTCF is speculated based upon its impact on critical genes like *p53, Myc, BRCA1, p19/ARF* involved in cancer onset and progression ([@b0020], [@b0115], [@b0205], [@b0180]).

Recent studies suggest that overexpression of CTCF contributes to tumor development in breast cancer by downregulating *HOXA10* and H3K27me3 expressions ([@b0165], [@b0120]). Interestingly, the repression of CTCF leads to the overexpression of *BAX* and eventual apoptosis ([@b0035]).

Mutations have been detected in CTCF chromatin binding sites (CBS) in multiple cancers, especially mutations of A-T base pairs ([@b0100]). The loss of CTCF poly ADP-ribosyltion in breast cancer leading to the expression of both 180-kDa and 130-kDa in comparison to only 180-kDa CTCF in normal breast tissues likely contributes to the progression of breast cancer ([@b0040]).

Although CTCF-130-kDa or Rb2/p130 can be used as the biomarker for the cancer progression, the utility of CTCF-130-kDa as the disease prognosis biomarkers remain to be investigated ([@b0135], [@b0230], [@b0270], [@b0280], [@b0105]). Recent studies show that CTCF regulates changes of the 3D genome organization ([@b0275], [@b0235], [@b0130]) in the pathogenesis of disease ([@b0240], [@b0150], [@b0250]).

In the present study, we screened the hotspot coding regions of *CTCF* gene for the mutation(s) by PCR-SSCP in 155 cases of female breast carcinoma along with corresponding adjacent healthy control. We found 25 (16.1%) missense and silent mutations in female breast cancer tissues as shown in the [table 2](#t0010){ref-type="table"}. The mutation(s) were identified at codon 72 leading to Gln \> His (G \> T), and at codon 1455 leading to Ser \> Ser(C \> T). The missense codon mutations in *CTCF* zinc finger domain 3, observed in the present study may impact the CTCF binding to the promoters of genes related to cellular proliferation like *MYC*, *PLK*, *PIM-1*, *p19ARF*, and *Igf2/H19* ([Fig. 4](#f0020){ref-type="fig"}) ([@b0055]). The mutation(s) may also have resulted in repression of the wild-type allele and low/ no protein expression ([@b0005]). Moreover, our data exhibited the altered expression profiles of *CTCF* which may be due to the result of potential mutation(s) in the *CTCF* exonic region and thus can contribute in the progression of breast cancer as shown in an early study ([@b0255]).

Importantly, we observed that *CTCF* mutations were only found in breast cancer tissue and not in healthy tissues. The analysis of potential relationship with the patient's ages, menopausal status, histological types, tumor sizes, histological grades, tumor stages, lymph node metastases, steroid receptors (*ER* & *PR*) and *Her2/neu* amplifications to elucidate the role of mutation(s) in *CTCF* gene in the progression of breast cancer revealed a significant relationship between *CTCF* mutations and patients' menopausal status *(p* = 0.02), tumor stages (*p* = 0.03), lymph node metastases (*p* = 0.03) and *ER* (*p* = 0.04). The significant association with the clinical parameters further emphasizes the link between CTCF and breast cancer progression. No significant association was found with patient ages, histological types, tumor sizes, histological grades, *PR* and *Her2/neu* amplifications.

CTCF protein expression analysis was performed to explore the possible role of CTCF in female breast cancer cases and also to define the biomarker property.

An early study showed moderate to strong nuclear staining of CTCF protein ([@b0005]). More than 80% of the cases included in our study showed a low or moderate *CTCF* expression which was significantly linked with histological grades (*p* = 0.04), tumor stages (p = 0.04), lymph node involvements (*p* = 0.03) and *ER* (*p* = 0.04). No significant association was observed with parameters such as age, menopausal status, histological types, tumor sizes, PR status and Her2/neu amplification of breast cancer progression ([Table 5](#t0025){ref-type="table"}) suggesting the involvement of detected mutations in expression and altered formations of the protein contributing to the onset and progression of breast cancer which is in agreement with the findings of an early study ([@b0255]).

A significant association found between *CTCF* mutation and protein expression in the low level (+) category of protein expression (*p* = 0.03), whereas no significant association with the moderate (++) and high level (+++) of protein expression suggest that the progression of breast cancer may be related to the lower level of CTCF protein expression indicating towards the anti-proliferative activity of *CTCF*, and a potent breast cancer susceptible genes. The altered expression profiles of CTCF showing mainly nuclear expression in the current study are in agreement with the earlier studies using immunofluorescence to without any cytoplasmic staining ([@b0295]). In the present study, we found an association between CTCF expression and histological grade in the high percentage of low-grade tumors having less proliferative activity showing positive nuclear expression, whereas high-grade tumors primarily showed low or no expression. Our results are concordant with early reports indicating the ability of CTCF to inhibit cell growth and proliferation ([@b0210]).

5. Conclusions {#s0070}
==============

Our study showed mutations (missense Gln \> His, G \> T and silent Ser \> Ser, C \> T) of the *CTCF* gene in Indian female breast cancer cases. The detected mutations showed that 16 (64%) mutations had a statistically significant association with low or no expression for CTCF when analyzed with IHC data. The findings suggest that *CTCF* may be a tumor suppressor gene and its inactivation may play an essential role in the progression of breast carcinoma. However, further clinical studies with larger sample size are needed to elucidate the fundamental role of *CTCF* gene in the breast cancer onset and progression in Indian population.

Acknowledgments {#s0075}
===============

The author would like to thank the Indian Council of Medical Research (10.13039/501100001411ICMR), Government of India, New Delhi India (grant number 3/2/2/61/2011/MCD-3), for providing the fund for this study. The authors would like to thank all the breast cancer patients who participated in the study, and without whom the study would not have been possible.

Declaration of Competing Interest {#s0080}
=================================

All authors have read and approved the final manuscript and there is no conflict of interest.

Peer review under responsibility of King Saud University.

[^1]: P-value \< 0.05\*\* was considered significant.
